Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 10/20 | 0.40 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13002105 | 0.99 | FURIN (0.39) | FURINMAP1LC3BNPY1RNPY2RNPY4R | |
| SCHEMBL10270090 | 0.99 | FURIN (0.39) | FURINMAP1LC3BNPY1RNPY2RNPY4R | |
| SCHEMBL9943154 | 0.93 | FURIN (0.46) | FURINMAP1LC3BNPY1RNPY2RNPY4R | |
| SCHEMBL12629537 | 0.92 | FURIN (0.37) | FURINMAP1LC3BNPY1RNPY2RNPY4R | |
| SCHEMBL12568288 | 0.92 | FURIN (0.37) | FURINMAP1LC3BNPY1RNPY2RNPY4R | |
| SCHEMBL26008568 | 0.90 | MAP1LC3B (0.40) | FURINMAP1LC3BFAPHTT | |
| SCHEMBL26009307 | 0.90 | MAP1LC3B (0.40) | FURINMAP1LC3BFAPHTT | |
| SCHEMBL16925417 | 0.89 | MAP1LC3B (0.42) | FURINMAP1LC3BFAP | |
| SCHEMBL19982142 | 0.89 | MAP1LC3B (0.41) | MAP1LC3BFAP | |
| SCHEMBL13884204 | 0.89 | MAP1LC3B (0.38) | FURINMAP1LC3BNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398228-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | FURIN 2298/4885MAP1LC3B 224/4885NPY1R 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.